Study of CS-3150 in Patients With Essential Hypertension

Summary

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.

Timeline

Start

2016-09

Primary completion

2017-07-11

Completion

2017-07-11

Outcome

Met primary endpoint

paper Esaxerenone 2.5 mg/day was noninferior to eplerenone for reductions in sitting and 24-hour BP. PMID 31786983 ↗

Publications

• Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2020 Jan;75(1):51-58. doi: 10.1161/HYPERTENSIONAHA.119.13569. Epub 2019 Dec 2.

Drugs

Indications